Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion | PLOS ONE
![Frontiers | Delicate Balances in Cancer Chemotherapy: Modeling Immune Recruitment and Emergence of Systemic Drug Resistance Frontiers | Delicate Balances in Cancer Chemotherapy: Modeling Immune Recruitment and Emergence of Systemic Drug Resistance](https://www.frontiersin.org/files/Articles/531533/fimmu-11-01376-HTML/image_m/fimmu-11-01376-g001.jpg)
Frontiers | Delicate Balances in Cancer Chemotherapy: Modeling Immune Recruitment and Emergence of Systemic Drug Resistance
![Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project | SpringerLink Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12325-018-0844-4/MediaObjects/12325_2018_844_Fig1_HTML.png)
Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project | SpringerLink
![Cancers | Free Full-Text | Metronomic Chemotherapy Modulates Clonal Interactions to Prevent Drug Resistance in Non-Small Cell Lung Cancer Cancers | Free Full-Text | Metronomic Chemotherapy Modulates Clonal Interactions to Prevent Drug Resistance in Non-Small Cell Lung Cancer](https://www.mdpi.com/cancers/cancers-13-02239/article_deploy/html/images/cancers-13-02239-g001.png)
Cancers | Free Full-Text | Metronomic Chemotherapy Modulates Clonal Interactions to Prevent Drug Resistance in Non-Small Cell Lung Cancer
![JCM | Free Full-Text | Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows JCM | Free Full-Text | Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows](https://www.mdpi.com/jcm/jcm-11-04710/article_deploy/html/images/jcm-11-04710-g001.png)
JCM | Free Full-Text | Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows
![Metronomic Chemotherapy Enhances Antitumor Effects of Cancer Vaccine by Depleting Regulatory T Lymphocytes and Inhibiting Tumor Angiogenesis: Molecular Therapy Metronomic Chemotherapy Enhances Antitumor Effects of Cancer Vaccine by Depleting Regulatory T Lymphocytes and Inhibiting Tumor Angiogenesis: Molecular Therapy](https://www.cell.com/cms/attachment/3a91c075-8237-4eb6-b670-c37ffa41b28b/gr1_lrg.jpg)
Metronomic Chemotherapy Enhances Antitumor Effects of Cancer Vaccine by Depleting Regulatory T Lymphocytes and Inhibiting Tumor Angiogenesis: Molecular Therapy
![Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial - The Lancet Global Health Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial - The Lancet Global Health](https://www.thelancet.com/cms/attachment/adf6e5eb-e319-4d4d-a3ac-163ab0d59d87/gr3_lrg.gif)
Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial - The Lancet Global Health
![Different mechanisms of action of a metronomic chemotherapy. (modified... | Download Scientific Diagram Different mechanisms of action of a metronomic chemotherapy. (modified... | Download Scientific Diagram](https://www.researchgate.net/publication/269781363/figure/fig2/AS:486208800333826@1492932619617/Different-mechanisms-of-action-of-a-metronomic-chemotherapy-modified-from-127.png)
Different mechanisms of action of a metronomic chemotherapy. (modified... | Download Scientific Diagram
![Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial - The Lancet Global Health Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial - The Lancet Global Health](https://www.thelancet.com/cms/attachment/41eb5913-9ab4-4b87-99a3-c61d2cb967fa/gr1_lrg.gif)
Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial - The Lancet Global Health
![Metronomic Maintenance for High-Risk Pediatric Malignancies: One Size Will Not Fit All: Trends in Cancer Metronomic Maintenance for High-Risk Pediatric Malignancies: One Size Will Not Fit All: Trends in Cancer](https://www.cell.com/cms/asset/e7ec15aa-fc88-47ae-811c-48521199204c/gr1.jpg)
Metronomic Maintenance for High-Risk Pediatric Malignancies: One Size Will Not Fit All: Trends in Cancer
![Cancers | Free Full-Text | Metronomic Anti-Cancer Therapy: A Multimodal Therapy Governed by the Tumor Microenvironment Cancers | Free Full-Text | Metronomic Anti-Cancer Therapy: A Multimodal Therapy Governed by the Tumor Microenvironment](https://www.mdpi.com/cancers/cancers-13-05414/article_deploy/html/images/cancers-13-05414-g001.png)
Cancers | Free Full-Text | Metronomic Anti-Cancer Therapy: A Multimodal Therapy Governed by the Tumor Microenvironment
![Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial - The Lancet Global Health Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial - The Lancet Global Health](https://www.thelancet.com/cms/attachment/e977474a-6e1f-4500-b5df-bcde846c02df/gr1.gif)